Therefore, we hypothesized that prognosis may be improved through the use of immune checkpoint inhibitors (anti PD-1/PD-L1 antibodies) in DDEC with MMR deficiency. The gene discussed is CD274; the disease is mismatch repair cancer syndrome 1.